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BACKGROUND: Testicular germ cell tumour (TGCT) is the most common malignant tumour in young males. Although aberrant DNA
methylation is implicated in the pathophysiology of many cancers, only a limited number of genes are known to be epigenetically
changed in TGCT. This report documents the genome-wide analysis of differential methylation in an in vitro model culture system.
Interesting genes were validated in TGCT patient samples.
METHODS: In this study, we used methylated DNA immunoprecipitation (MeDIP) and whole-genome tiling arrays to identify
differentially methylated regions (DMRs).
RESULTS: We identified 35208 DMRs. However, only a small number of DMRs mapped to promoters. A genome-wide analysis of
gene expression revealed a group of differentially expressed genes that were regulated by DNA methylation. We identified several
candidate genes, including APOLD1, PCDH10 and RGAG1, which were dysregulated in TGCT patient samples. Surprisingly, APOLD1
had previously been mapped to the TGCT susceptibility locus at 12p13.1, suggesting that it may be important in TGCT pathogenesis.
We also observed aberrant methylation in the loci of some non-coding RNAs (ncRNAs). One of the ncRNAs, hsa-mir-199a, was
downregulated in TGCT patient samples, and also in our in vitro model culture system.
CONCLUSION: This report is the first application of MeDIP-chip for identifying epigenetically regulated genes and ncRNAs in TGCT.
We also demonstrated the function of intergenic and intronic DMRs in the regulation of ncRNAs.
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Testicular germ cell tumour (TGCT) is an invasive germ cell
tumour histologically classified as seminoma and non-seminoma.
Non-seminomatous tumours can be further sub-classified into
embryonal carcinoma, teratoma, choriocarcinoma and yolk-sac
tumour. Most non-seminomatous tumours include multiple cell
types. Embryonal carcinoma is the most frequent non-seminoma-
tous tumour. It represents B87% of non-seminoma (Bosl and
Motzer, 1997). Few seminomatous cell lines have been identified to
date; several embryonal carcinoma cell lines have been established
and shown to be useful for pathobiological and clinical studies
(Andrews et al, 2005). Ntera2 (NT2) is one of the established
pluripotent human testicular embryonal carcinoma cell lines. This
cell line has been extensively used in research on TGCT (Burger
et al, 1998; Koch et al, 2003; Skotheim et al, 2005). In this study, we
used NT2 as a cell model to study differential methylation in
embryonal carcinoma.
Unlike many cancers that peak during old age, TGCT is common
in young males. Risk factors include cryptorchidism, prenatal
exposure to diethylstilbestrol and genetic factors, such as locus
Xq27 that increases susceptibility to develop TGCT (Rapley et al,
2000; Horwich et al, 2006). DNA mutation may be one of the
causes of TGCT; however, accumulating information suggests a
more prominent role for epigenetic alteration as a factor in
tumourigenesis, including TGCT (Feinberg et al, 2006; Esteller,
2007). Previous reports on aberrant methylation of tumour-
suppressor genes/oncogenes provide information of an epigenetic
role in tumour development. Many studies focused on individual
target genes. The first genome-wide study of DNA methylation in
TGCT used the technique of restriction landmark genome
scanning (Smiraglia et al, 2002). However, no report of global
high-resolution analysis of methylation changes in TGCT has been
published. Tiling array technology permits the elucidation of
differentially methylated regions (DMRs) of the whole genome
(Weber et al, 2005; Zhang et al, 2006; Cokus et al, 2008) by the
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methylated DNA immunoprecipitation (MeDIP), in which methy-
lated DNA is enriched by the use of antibodies directed against
5-methylcytidine and hybridised to custom arrays, such as
promoter arrays or CpG island microarrays (Yan et al, 2002;
Jacinto et al, 2007; Irizarry et al, 2008). These whole-genome
approaches are powerful tools for the identification of differen-
tially methylated genes that may be important in tumourigenesis.
In this report, we used MeDIP, in combination with human
tiling microarrays (MeDIP-chip) that allow coverage of the entire
human genome, to elucidate DMRs. This approach allows the
identification of not only differentially methylated promoters and
gene-associated CpG islands but also differentially methylated
non-coding RNAs (ncRNAs), such as microRNAs (miRNAs). An
increasing number of reports suggest that miRNAs may have
pivotal roles in tumour progression and development, including
the regulation of neoplastic transformation and metastasis
(Ma et al, 2007; Huang et al, 2008; Varambally et al, 2008).
Some miRNAs are epigenetically silenced in cancer cells as
a result of cancer-specific hypermethylation (Han et al,
2007; Lujambio et al, 2008; Toyota et al, 2008). As most miRNAs
are located in intergenic or intronic regions, they were not
identified in previous studies using promoter or CpG island a
rrays. To validate the clinical usefulness of our approach, we
documented methylation and expression changes of three novel
genes and a miRNA in a normal and tumourous testicular tissue.
Our genome-wide approach demonstrates the use of MeDIP-chip
integrated with expression profiling as a tool for identifying
methylation-regulated genes and ncRNAs that might be important
in disease.
MATERIALS AND METHODS
Primary tumour specimens, cell cultures and drug
treatment
Genomic DNA (17 cases) and RNA (18 cases) samples obtained
from TGCT patients were purchased from Oncomatrix (San
Marcos, CA, USA). Normal testicular DNA (6 cases) and RNA
(8 cases) were purchased from Biochain (Hayward, CA, USA) and
Zyagen (San Diego, CA, USA), respectively. RNAs of tumour and
normal adjacent tissues of other tumour types were purchased
from Ambion (Austin, TX, USA). Each RNA sample was isolated
from a single individual. Cell culture system Ntera2 (NT2), Tera-1
and normal human testis cell line CRL-7002 (HT) were purchased
from ATCC (Manassas, VA, USA) and cultured in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS
and incubated in a 371C humidified incubator supplied with 5%
CO2. For demethylation analysis, 1 10
5 NT2 cells were seeded for
24h and treated with 1–5mM of 5-aza-2-deoxycytidine (Sigma,
St Louis, MO, USA) for 72h.
MeDIP and microarray hybridisation
Methylated DNA immunoprecipitation was performed as
described previously (Weber et al, 2005). Briefly, genomic DNA
was sheared by sonication on ice to generate random fragments of
100–500bp. Sonicated DNA of 5mg was used for IP. Heat-
denatured DNA was incubated with 10ml of mouse anti-5-
methylcytidine monoclonal antibody (Eurogenetec, San Diego,
CA, USA) in 1  IP buffer (10mM Na-Phosphate pH 7.0, 140mM
NaCl and 0.05% Triton X-100) with periodic shaking for 2h at 41C.
Sheep anti-mouse IgG-conjugated Dynabeads (Invitrogen) were
added to the IP buffer and incubated for an additional 2h. The
beads were washed thrice with 700ml1   IP buffer and then
resuspended in 250ml digestion buffer (50mM Tris, pH 8.0, 10mM
EDTA, 0.5% SDS). The antibodies were digested with 80mgo f
proteinase-K for 3h at 501C. DNA was extracted with phenol–
chloroform and precipitated with ethanol. Precipitated DNA was
resuspended in water and used for real-time quantitative (qPCR)
(for validation of IP efficiency) or for microarray hybridisation.
Several positive and negative control loci were used for confirma-
tion of IP efficiency before hybridising to microarrays (Supple-
mentary Figure 1A). The immunoprecipitated DNA was amplified,
labelled and hybridised to Human Tiling Array 2.0R Chips
(Affymetrix, Santa Clara, CA, USA) sequentially, as suggested by
Affymetrix ChIP-chip protocol. Triplicate sets of hybridisation
were performed from three independent MeDIP experiments for
each cell line. Both tiling and expression arrays were washed and
stained on the Affymetrix Fluidic Station 450 and Chips were
scanned on GeneChip Scanner GCS3000 (Affymetrix).
Tiling array data analysis
Raw CEL data files obtained from tiling array experiments were
analysed using Tiling Analysis Software (TAS) (Affymetrix). Arrays
from each group (cancer vs normal) were quantile normalised, and
differential methylation between cancer and normal groups was
compared by choosing the ‘two-sample comparison analysis’ option
in TAS. A two-sided test was conducted to evaluate both
hypermethylation and hypomethylation. A bandwidth was set at
275, such that the sliding window (2 bandwidthþ1) of the
analysis is 551. Transfrags (or DMRs) were generated by interval
analysis with a P-value cutoff at 20 (Po0.01), maximum gap at 250
and a minimum run at 50. Transfrags generated by the P-value
cutoff with a positive signal difference were defined as hypermethy-
lated, whereas those of negative difference were defined as
hypomethylated. Genomic bisulphite sequencing was performed to
confirm the sensitivity of the observed DMRs (Supplementary
Figure 1C). Mapping of DMRs to Refseq, CpG island, promoter,
miRNA and small nucleolar RNA (snoRNA) was performed using
the Table Browser function embedded in UCSC Genome Bio-
informatics (Santa Cruz, CA, USA; http://genome.ucsc.edu/cgi-bin/
hgTables?command¼start) or by our customised web-based tool
TileMapper (http://tilemapper.nichd.nih.gov/tilemapper) designed
specifically for transfrag mapping. Promoter annotation was retrieved
from Genomatix (San Jose, CA, USA; http://www.genomatix.de),
and the coordination of each promoter was stored in BED files.
Annotations of Refseq, CpG island, miRNA and snoRNA were
retrieved from the UCSC Genome Browser. All analyses were based
on human genome Build 35.1.
Expression array hybridisation and data analysis
Total RNA was extracted from NT2 and HT cells with Trizol
reagent and analysed using Bioanalyzer (Agilent, Santa Clara, CA,
USA). DNaseI-treated RNA of 3mg was amplified and the resulting
cRNA was biotin-labelled and hybridised to Human Genome U133
Plus 2.0 Arrays (Affymetrix). Triplicate sets of hybridisation were
performed for each cell line, and the raw data were normalised by
robust multiarray average algorithm and analysed in Partek
Genomics Suite Software (St Louis, MO, USA). Differential gene
expression was evaluated using one-way ANOVA. Expression fold
change of differentially methylated genes was represented by
probing the most significant P-value. Differentially expressed
genes were confirmed by real-time PCR (Supplementary Table 3).
Genomic bisulphite sequencing and methylation-specific PCR
Genomic DNA (400ng) was treated with sodium bisulphite using
the EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA,
USA). Bisulphite-treated DNA (80–100ng) was used for PCR
amplification. For bisulphite sequencing, the PCR product was
TOPO-cloned into the pCR4 vector (Invitrogen) and 5–10 positive
clones were sequenced. Graphics of CpG methylation were
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methylation-specific PCR (MSP), methylated- and unmethylated-
specific primers were designed in the same genomic region as in
bisulphite sequencing. Methylation-specific PCR products were
resolved in 2.5% agarose gel.
Quantitative real-time RT–PCR
Total RNA (1mg) was primed by random hexamers and converted
into cDNA by SuperScript III (Invitrogen). The SYBR green-based
real-time PCR was performed in an Applied Biosystems 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA), and the level of gene expression was normalised by 18S
rRNA. For real-time quantification of miRNAs, total RNA was
extracted using the mirVana miRNA Isolation Kit (Ambion).
cDNA was synthesised from 1mg of total RNA using miRNA-
specific primers with the TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems) and normalised by hsa-mir-191. All
PCR primers are listed in Supplementary Table 4.
Statistical analysis
The P-value of tiling array analysis was computed using TAS, which
uses a Hodges–Lehmann estimator associated with the Wilcoxon
rank-sum test to compute the fold enrichment between treatment
(cancer) and control (normal) groups. Po0.01 was considered to be
statistically significant. The P-value of expression microarray
analysis was determined by one-way ANOVA by comparing
triplicate sets of normalised normal and cancer cells. The differential
expression of APOLD1, PCDH10, RGAG1 and hsa-mir-199a-2 in
TGCT patients as determined by qPCR was analysed by two-tailed
Student’s t-test. Po0.05 was considered statistically significant.
RESULTS
Identification of DMRs in NT2 cells
The pattern of DNA methylation changes substantially when cells
become cancerous. To better understand the global change of DNA
methylation and the effect on transcription, genome-wide methy-
lation and expression profiling were examined in an in vitro
pluripotent cell model Ntera2 (NT2), which is an embryonal
carcinoma derived from a testicular cancer patient, and in normal
testis cells (HT) (Andrews, 1998). Methylated DNA fragments in
the genome of each sample were enriched by MeDIP, followed by
whole-genome interrogation by hybridising to tiling microarrays
that cover the entire non-repetitive human genome.
To highlight the aberrant methylated regions in NT2 cells and to
allow downstream processing and analyses, DMR was compiled on
the basis of the P-value cutoff (Po0.01). We identified 22452
hypermethylated and 12756 hypomethylated DMRs in the cancer
genome. To validate the tiling array results, we randomly selected a
number of DMRs at different gene loci including EBNA1BP2,
PQLC2, HOXC10, HOXA7, OSR1, GAD1, ZSWIM2, and an
intergenic region for genomic bisulphite sequencing. The results
confirmed the tiling array data and documented it to be a sensitive
and reliable tool for detecting DMRs with a P-value cutoff at 0.01
(Supplementary Figure 1).
Global DMR differential methylation allowed the analysis of the
chromosomal distribution of hypermethylation and hypomethylation,
represented by the percentage of the total length of DMRs per 500-kb
interval. As anticipated, DMRs were not evenly distributed in the
genome. We observed chromosomal regions that were preferentially
methylated or demethylated. For example, chromosomes 1p34.3,
1q43–4, 7q36.2–3, 16p13.2 and 21q22.2–3 were intensively hyper-
methylated, whereas chromosomes 5q13.2, 18q11.2–12.1 and
19q13.31 were more hypomethylated. Some chromosomes, such as
3, 10, 13, 14 and Y, exhibited fewer DMRs (Supplementary Figure 2).
Aberrant promoter methylation is usually linked to an altered
chromosomal state, and thus to transcriptional gene silencing.
To determine whether DMRs preferentially occurred in promoters,
a genome-wide mapping of DMRs was performed. Intriguingly,
most of the human genome DMRs, 92.9% of hypermethylated and
88.2% of hypomethylated DMRs, were mapped to genomic regions
without any gene annotation (intergenic). Only 5.2% of hyper-
methylated and 9.5% of hypomethylated DMRs were mapped to
annotated Refseq, including exons and introns. However, a low
percentage of DMRs, 1.9% (414) of hypermethylated and 2.3% (279)
of hypomethylated DMRs, mapped to promoter regions of known
genes (Figure 1A). Thus, we identified a sequence of various
chromosomal epigenetic hotspots and many novel DMRs that reside
in gene bodies, promoters, CpG islands and intergenic regions.
Differentially methylated CpG islands and promoters
Although the effect of DNA methylation in intergenic regions is
less clear, aberrant methylation in promoter regions has frequently
been linked to altered transcriptional activity. About half of the
known human gene promoters are associated with CpG islands
(Larsen et al, 1992). These CpG islands are protected from de novo
methylation in normal tissues, but often acquire methylation in
cancer cells that leads to gene silencing. Among the 35208 DMRs
identified in our study, 410 (295 hypermethylated DMRs and 115
hypomethylated DMRs) overlapped with CpG islands (Supple-
mentary Table 1). However, only 79 (B27%) hypermethylated
CpG islands and 13 (B13%) hypomethylated CpG islands were
associated with gene promoters (Figure 1B). The other differen-
tially methylated CpG islands resided either inside genes or in non-
genic regions. For promoter-associated CpG islands, a number of
them, including those of NTF3, FGF, OSR1, HOXA6, NPY and WT1,
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other cancer types (Mares et al, 2001; Bibikova et al, 2006; Oka
et al, 2006; Houshdaran et al, 2007; Illingworth et al, 2008). Our
study also identified many CpG islands that were not previously
shown to be differentially methylated, such as CXCL5, EID1 and
TRHDE.
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Figure 2 Gene expression of differentially methylated genes. (A) Expression of hypermethylated and hypomethylated genes. Genes are divided into
three groups on the basis of their expression. Group A: hypermethylated genes (19%) are downregulated (fold change 42), whereas hypomethylated genes
(20%) are upregulated (fold change o 2). Group B: hypermethylated genes (25%) are upregulated, whereas hypomethylated genes (22%) are
downregulated. Group C: the expression fold change of differentially methylated genes is marginal (fold change between  2 and 2). Nine genes of group A
and eight genes of group B are randomly selected and the effect of demethylation is examined, as shown in B and C. (Panel B) Effect of 5-aza treatment on
the expression of nine group A genes. NT2 cancer cells are treated with 1–5mM 5-aza for 72h. (Panel C) Effect of 5-aza treatment on the expression of
eight group B genes. ‘þ’ indicates the promoters that are associated with CpG islands. ‘ ’ indicates the absence of CpG islands in the promoters. Error bars
indicate s.e.m. of triplicate experiments.
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and Il2, lacked CpG islands in their promoters but were regulated
by CpG methylation (Bruniquel and Schwartz, 2003; Hattori et al,
2004). We undertook a more comprehensive DMR mapping
strategy not limited to CpG islands within gene promoters. A
total of 693 genes (414 hypermethylated and 279 hypomethylated)
were differentially methylated in promoters (Figure 1C and
Supplementary Table 2). Compared with previous reports limited
to CpG islands, more genes exhibited differential methylation in
promoters, which was not associated with CpG islands. Therefore,
aberrant promoter methylation is not restricted to CpG islands.
Variability in the expression of differentially methylated
genes
To assess the effect of methylation on transcriptional activity in
cancer cells, we carried out a genome-wide analysis of gene
expression by microarray. Expression data were then compared
with DMR data. On the basis of the relative expression level, genes
with differentially methylated promoters could be divided into
three groups (Figure 2A). In group A, 19% of hypermethylated
genes showed more than two-fold downregulation, whereas 20% of
hypomethylated genes showed more than two-fold upregulation.
In group B, 25% of hypermethylated genes were upregulated more
than two-fold, whereas 22% of hypomethylated genes were
downregulated by more than two-fold. In group C, which accounts
for 56% of hypermethylated and 58% of hypomethylated genes, the
change of expression was marginal (fold change ranged from  2
to 2). The expression of genes in this group seemed to be
independent of promoter methylation.
To confirm the effect of CpG methylation on gene expression, we
randomly selected eight genes from group A and nine genes from
group B, and assessed whether treatment with the demethylating
agent 5-aza would restore transcriptional activity. For group A
genes, 5-aza treatment restored the expression of eight of the nine
selected genes (Figure 2B). For group B, expression of only two of
the eight selected genes was restored by 5-aza treatment (Figure 2C).
Transcription of most of the genes in group A, but not in group B,
suggests a functional role for DNA methylation. The effect of
demethylation by 5-aza on gene expression seemed to be
independent of the presence of CpG islands.
Identification of novel aberrantly methylated genes in
primary TGCT
The testicular embryonal carcinoma NT2 cell is one of the well-
studied testicular germ cell neoplasms (Andrews, 1998). On the
basis of DMR data, we identified novel hypermethylated candidate
genes that might be potential epigenetic markers for TGCT. We
selected candidate genes on the basis of the following criteria:
first, genes with hypermethylated promoters (Figure 3A); second,
expression of genes that are downregulated and in which
demethylation by 5-aza restored gene expression (Figure 2B);
third, a biological role in testicular cancer was not previously
described. The candidate genes were validated in normal testis
biopsies and in primary TGCT samples. On the basis of these
criteria, we identified three candidate genes, namely APOLD1,
PCDH10 and RGAG1, for further investigation in the primary
TGCT tissue. Promoters of APOLD1 and PCDH10 were associated
with CpG islands. In contrast, RGAG1 lacks any CpG island in its
promoter region. Hypermethylation of the promoters of these
three genes in NT2 cells was confirmed by bisulphite sequencing
(Figure 3A). In addition, we examined the methylation status of
these genes in another testicular embryonal carcinoma Tera-1.
Analogous to NT2 cells, hypermethylation of the three genes in
Tera-1 cells was observed (Supplementary Figure 5). In addition,
the methylation status of genes in cultured normal testicular cells
was similar to that of normal testis tissue, indicating that
methylation of these loci was not changed during cell culture
(Figure 3A and Supplementary Figure 5). We investigated whether
gene expression was altered in a primary TGCT tissue. The
expression of these three genes, similar to the results observed in
cell culture, was significantly downregulated in both seminoma
(n¼8; APOLD1: Po0.005; PCDH10: Po0.05; RGAG1: Po0.001 by
two-tailed Student’s t-test) and embryonal carcinoma (n¼9;
APOLD1: Po0.005; PCDH10: Po0.05; RGAG1: Po0.0005 by two-
tailed Student’s t-test) and in a case of yolk-sac tumour (n¼1)
compared with normal testicular tissue (n¼8) (Figure 3B).
Among the candidate genes, hypermethylation of PCDH10 was
implicated in other cancers (Ying et al, 2007; Yu et al, 2009). The
present result supports the role of this putative tumour-suppressor
gene in testicular cancer. APOLD1 is an uncharacterised gene and
its biological function is currently unknown. To examine whether
aberrant hypermethylation of APOLD1 is also observed in primary
TGCT, the methylation status of the promoter of APOLD1 was
measured by MSP (Figure 3C, upper panel). Hypermethylation of
the APOLD1 promoter was confirmed in 71% (n¼17) of TGCT
specimens. The APOLD1 promoter was unmethylated in all cases
of normal testicular tissue (n¼6). To validate the result of MSP, a
pair of tumour and normal tissues was selected and analysed by
bisulphite sequencing (Figure 3C, lower panel). Consistent with the
MSP result, bisulphite sequencing showed that this gene was
almost unmethylated in normal testicular tissues, but exhibited
partial methylation in primary tumours. The observations of
hypermethylation and downregulation of APOLD1 in primary
TGCT tissues suggest that DNA methylation has a crucial role in
silencing this gene. In a preliminary screening of various primary
tumours, the expression of APOLD1 was downregulated in
tumours of not only the testis but also those of the ovary,
lymphoma, kidney, bladder and cervix (Figure 3D). RNA samples
of each tumour type and the corresponding normal adjacent tissue
were collected from a single individual; therefore, the role of
APOLD1 as a tumour-suppressor gene awaits further confirmation
with examples of more tumour specimens.
Differentially methylated ncRNAs and their dysregulation
in cancer
The fact that the majority of DMRs occur in non-repetitive intergenic
and intronic regions raises the question of their potential regulatory
function. We proposed that intergenic and intronic methylation may
have a role in regulating ncRNAs. There are several groups of
ncRNAs involved in many cellular processes. microRNA is a class of
short ncRNAs that has been known to destabilise or repress
translation of mRNA at the post-transcriptional level. To explore the
role of intergenic or intronic DMRs, we mapped the identified DMRs
to the miRBase Registry. The loci of three miRNAs, namely hsa-mir-
199a-2, hsa-mir-124a-2 and hsa-mir-184, were found to be linked to
hypermethylated DMRs (Figure 4A). Hypermethylation of these
three miRNAs in the model culture system (NT2) was confirmed by
genomic bisulphite sequencing. To examine the effect of hyper-
methylation on the expression of miRNA, the level of mature
miRNAs in cancer and normal cells was measured by real-time
q P C R .A m o n gt h et h r e em i R N A s ,o n l yhsa-mir-199a-2 was down-
regulated in cancer cells (741-fold downregulation), whereas
hsa-mir-124a-2 and hsa-mir-184 showed a 19562- and 37-fold
upregulation, respectively (Figure 4B). Treatment of NT2 cancer cells
with 5-aza upregulated the expression of hsa-mir-199a-2 by 42-fold,
indicating that the expression of this miRNA was suppressed
by methylation (Figure 4C). Treatment with 5-aza also upregulated
the expression of hsa-mir-184 by 25-fold but had no effect on the
expression of hsa-mir-124a-2.
hsa-mir-199a-2 may be a candidate gene that is epigenetically
regulated in TGCT. We thus studied its expression in primary
TGCT tissue. By real-time qPCR, the expression level of hsa-mir-
199a-2, as normalised with that of hsa-mir-191, was downregulated
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t-test), and more significantly in seminoma (n¼8; Po0.00005 by
two-tailed Student’s t-test) (Figure 4D).
In addition to miRNA, we also mapped non-genic DMRs to
snoRNA-LBME-db, and three snoRNAs, namely HBII-240, ACA33
and ACA8, were hypomethylated (Supplementary Figure 3A).
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snoRNAs in cancer and normal cell lines revealed that HBII-240
and ACA33 were upregulated by approximately three-fold
(Supplementary Figure 3B). In a proportion of primary TGCT
tumours, we found that these three snoNRAs were also upregu-
lated as compared with normal testis tissue (Supplementary
Figure 4). The specific role of these snoRNAs in testicular germ
cell tumourigenesis remains to be elucidated.
DISCUSSION
Aberrant DNA methylation is common in cancer cells. This study
demonstrates a genome-wide approach for identification of
differentially methylated genes and ncRNAs using MeDIP-chip in
combination with global expression analysis.
CpG island hypermethylation results in changes in chromatin
accessibility and seems to repress gene transcription. In our study,
although many genes were differentially methylated, only 20% of
genes showed an association between hypermethylation and gene
repression. The role of DNA methylation on repression of these genes
was validated by treatment with 5-aza, which inhibited DNA
methylation and restored expression of the genes. We also
demonstrated another group of genes that, although hypermethylated
in their promoters, were insensitive to demethylation. The existence
of methylation-insensitive genes highlights the need to experimentally
link epigenetic changes to altered transcriptional activity.
Whole-genome tiling hybridisation allowed us to observe
widespread methylation changes. Only a small proportion of
DMRs were found in promoters of known genes. A substantial
number of DMRs were located in intronic or intergenic regions.
Methylation changes in intronic or intergenic regions previously
reported have largely been ignored because of failure to investigate
transcriptional consequences. The role of intergenic DMRs
remains an enigma. They may be a consequence of inappropriate
epigenetic change during transformation. They may have a role in
maintenance of genomic stability or chromatin condensation
(Ahuja et al, 1997; Ballestar and Esteller, 2002). Another possible
function of intronic and intergenic DMRs is the regulation of
genetic elements not identified by conventional algorithms. Many
ncRNAs are located in intronic and intergenic regions and their
regulation is unknown. In our study, DMRs were mapped to
current miRNA and snoRNA databases to explore whether
methylation changes occur in regions of ncRNAs. This allowed
identification of three hypermethylated miRNAs and three
hypomethylated snoRNAs.
Although the three miRNAs were hypermethylated, expression
and 5-aza treatment experiments indicated that only hsa-mir-199a-2
was suppressed by hypermethylation. The unexpected behaviour
of hsa-mir124a-2 and hsa-mir-184 could probably be explained by
the location of the partially methylated regions near the 30-end of
the transcribed locus, whereas the DMR of hsa-mir-199a-2 covers
the 50 upstream and transcribed locus. Studies of cancers report
that miRNA dysregulation is often associated with tumour
progression or metastasis, probably a consequence of post-
transcriptional silencing of target oncogenes or tumour-suppres-
sor genes (Mendell, 2005; Zhang et al, 2007). This study implicates
methylation as one of the causes.
Small nucleolar RNAs are another group of ncRNAs that guide
modification of rRNAs or spliceosomal RNAs. These conserved
small RNA regulators modify alternative splicing of many
transcripts (Bachellerie et al, 2002). In this study, the identification
of hypomethylation and enhanced expression of the three
snoRNAs suggest a potential relationship between cancer and
dysregulation of snoRNAs.
An in vitro cell culture system was exploited in this
study because of the ease of its manipulation. We recognise
that methylation changes in these cultured cells may not reflect
in vivo changes. Despite this, we found a number of differentially
methylated genes in the culture system, which were concordant
with those of tissue samples. Three hypermethylated genes,
PCDH10, APOLD1 and RGAG1, were investigated as
examples. These genes were silenced in primary TGCTs and their
expression was restored upon demethylation. PCDH10 encodes a
membrane protein for cell adhesion. It has been implicated to
be a tumour-suppressor gene in studies on nasopharyngeal,
oesophageal, breast, colorectal, cervical, lung and hepatocellular
carcinoma cell lines. Expression of PCDH10 in these cell lines was
suppressed by DNA hypermethylation (Ying et al, 2006). Interest-
ingly, it has also been identified as one of the deleted loci in
patients with autism (Morrow et al, 2008). Before this study,
RGAG1and APOLD1 were not known to be epigenetically silenced
in cancers. RGAG1 (also known as MART9) is an X-linked
retrotransposon-derived neogene of unknown function (Brandt
et al, 2005). Expressed sequence tags of RGAG1 were found
predominantly in the testis, suggesting that this retrogene might
be important in germ cell development. APOLD1 is another
uncharacterised gene identified in this study. Its open reading
frame encodes an apolipoprotein-L domain-containing protein,
the function of which is unknown. Remarkably, APOLD1 is located
in 12p13.1, a TGCT susceptibility locus previously identified by
genetic linkage analysis (Crockford et al, 2006). Although genetic
susceptibility loci in this gene have not been identified, the
coincidence of an epigenetically silenced gene in this locus may
provide a new insight into interactions between genetic and
epigenetic factors.
In summary, this study provides comprehensive data for
identification of both protein-coding genes and ncRNAs that are
epigenetically regulated by DNA methylation. Methylation occurs
in promoters and CpG islands, as well as in intragenic and
intergenic regions. Only a subset of hypermethylated genes is
directly regulated by DNA methylation. We also demonstrated
dysregulation of three candidate genes and a miRNA in primary
TGCTs. Two of the genes, APOLD1 and RGAG1, are novel genes,
the biological function of which needs further investigation.
hsa-mir-199a-2 is another developmentally regulated miRNA that
is implicated in cancer invasion (Migliore et al, 2008).
We now use the MeDIP-chip for identifying aberrant methyla-
tion in malignant TGCT patient samples targeting for DMRs
specific for cancer metastasis. Meanwhile, we identified potential
targets of hsa-mir-199a-2 that might be associated with cancer
invasion in TGCT (data unpublished).
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